Selected prospective and retrospective series investigating VLDRT for iNHL
| Reference . | Year . | Design . | RT fields . | Pathology summary . | No. of patients . | No. of sites . | Median follow-up (mo) . | ORR (%) . | CR (%) . | PR (%) . | Results . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| This study | 2021 | Retrospective | ISRT | 66% FL, 27% MZL, and 7% low-grade NOS | 250 | 299 | 26 | 90 | 68 | 22 | 2-y cumulative incidence of LP for overall, 25%; non-curable, 29%; potentially curable, 9% |
| 24,25 | 2014, 2021 | Randomized, phase 3, noninferiority of 4 Gy vs 24 Gy (FoRT) | IFRT | 56% FL, 7% MZL, 6% other (ie, CLL, DLBCL, HL), 12% no diagnosis possible, 21% with no central review | 281 | 315 | 74 | 81 | 49 | 32 | LPFS at 5 y: 89.9% after 24 Gy and 74.4% after 4 Gy (P < .001) |
| 21 | 2008 | Phase 2 | IFRT | 62% indolent (mostly FL) and 36% aggressive lymphoma | 36 | 47 | 5 | 86* | 48* | 38* | Median time to LP for the entire group, 15 mo |
| 19 | 2005 | Phase 2 | IFRT | SLL and CLL (n = 23), MZL (n = 18), MCL (n = 17), DLBCL (n = 13) | 71 | 177 | 9 | 93* | 56 | 37 | Median time to LP for iNHL, 23 mo |
| 18 | 2003 | Phase 2 (HORA-1) | IFRT | FL 90%, MZL 8%, lymphoplasmacytoid lymphoma 2% | 109 | 304 | 7 | 92 | 61 | 31 | Median time to LP, 25 mo |
| 17 | 2002 | Phase 2 | IFRT | 68% iNHL, 32% CLL | 22 | 31 | 8 | 87* | 74* | 13* | Median time to LP for full group, 22 mo |
| 35 | 2018 | Retrospective | 57% FL, 43% MZL | 47 | 50 | 21 | 90 | LPFS at 2 y for all patients, 91.1%; curative, 96.7%; palliative, 83.8% | |||
| 34 | 2013 | Retrospective | IFRT | 66% FL, 9% CLL or SLL, 10% MZL, 6% MCL, 8% other | 127 | 187 | 23 | 82 | 57 | 25 | Median time to first recurrence, 13.6 mo |
| 22 | 2011 | Retrospective | 56% indolent, 28% CLL, 13% aggressive, 2% of sites were other | 54 | 85 | 16 | 88* | 71 | 17 | LPFS at 2 years, 50% | |
| 20 | 2008 | Retrospective | IFRT | FL 85%, MZL 6%, MCL 6%, CLL 3% | 33 | 43 | 14 | 95 | 84 | 12 | Median time to LP, 9 mo |
| 15 | 2001 | Retrospective | IFRT | 100% low-grade lymphomas | 48 | 135 | 54 | 81 | 57 | 24 | LPFS at 2 y, 56% |
| Reference . | Year . | Design . | RT fields . | Pathology summary . | No. of patients . | No. of sites . | Median follow-up (mo) . | ORR (%) . | CR (%) . | PR (%) . | Results . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| This study | 2021 | Retrospective | ISRT | 66% FL, 27% MZL, and 7% low-grade NOS | 250 | 299 | 26 | 90 | 68 | 22 | 2-y cumulative incidence of LP for overall, 25%; non-curable, 29%; potentially curable, 9% |
| 24,25 | 2014, 2021 | Randomized, phase 3, noninferiority of 4 Gy vs 24 Gy (FoRT) | IFRT | 56% FL, 7% MZL, 6% other (ie, CLL, DLBCL, HL), 12% no diagnosis possible, 21% with no central review | 281 | 315 | 74 | 81 | 49 | 32 | LPFS at 5 y: 89.9% after 24 Gy and 74.4% after 4 Gy (P < .001) |
| 21 | 2008 | Phase 2 | IFRT | 62% indolent (mostly FL) and 36% aggressive lymphoma | 36 | 47 | 5 | 86* | 48* | 38* | Median time to LP for the entire group, 15 mo |
| 19 | 2005 | Phase 2 | IFRT | SLL and CLL (n = 23), MZL (n = 18), MCL (n = 17), DLBCL (n = 13) | 71 | 177 | 9 | 93* | 56 | 37 | Median time to LP for iNHL, 23 mo |
| 18 | 2003 | Phase 2 (HORA-1) | IFRT | FL 90%, MZL 8%, lymphoplasmacytoid lymphoma 2% | 109 | 304 | 7 | 92 | 61 | 31 | Median time to LP, 25 mo |
| 17 | 2002 | Phase 2 | IFRT | 68% iNHL, 32% CLL | 22 | 31 | 8 | 87* | 74* | 13* | Median time to LP for full group, 22 mo |
| 35 | 2018 | Retrospective | 57% FL, 43% MZL | 47 | 50 | 21 | 90 | LPFS at 2 y for all patients, 91.1%; curative, 96.7%; palliative, 83.8% | |||
| 34 | 2013 | Retrospective | IFRT | 66% FL, 9% CLL or SLL, 10% MZL, 6% MCL, 8% other | 127 | 187 | 23 | 82 | 57 | 25 | Median time to first recurrence, 13.6 mo |
| 22 | 2011 | Retrospective | 56% indolent, 28% CLL, 13% aggressive, 2% of sites were other | 54 | 85 | 16 | 88* | 71 | 17 | LPFS at 2 years, 50% | |
| 20 | 2008 | Retrospective | IFRT | FL 85%, MZL 6%, MCL 6%, CLL 3% | 33 | 43 | 14 | 95 | 84 | 12 | Median time to LP, 9 mo |
| 15 | 2001 | Retrospective | IFRT | 100% low-grade lymphomas | 48 | 135 | 54 | 81 | 57 | 24 | LPFS at 2 y, 56% |
LPFS, local progression-f ree survival.
Outcomes of only the indolent subgroup of studied patients.